Dermatologic toxicities of immune checkpoint inhibitors in genitourinary malignancies: The urologist–dermatologist interface

Immune checkpoint inhibitors have transformed the management of advanced genitourinary cancers but are frequently associated with dermatologic immune-related adverse events (irAEs). In this retrospective study of 80 patients, 42.5% developed cutaneous reactions, most commonly maculopapular rash and lichenoid eruptions. Severe (grade ≥3) irAEs correlated with superior oncologic responses. Prompt dermatologic consultation reduced treatment interruptions by 28%. Early recognition and multidisciplinary care are vital to maintain therapy continuity. Cutaneous irAEs may serve as visible biomarkers of immune activation, underscoring the importance of collaborative management between urologists and dermatologists in modern uro-oncologic practice.